Home › Funds › PFM Health Sciences, LP › INBX
PFM Health Sciences, LP position in INBX
INHIBRX BIOSCIENCES INC · Health Care
PFM Health Sciences, LP reported holding 320,331 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$32.1M, representing 3.28% of its reported portfolio and ranking #6 among its reported holdings. PFM Health Sciences, LP has disclosed INBX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How PFM Health Sciences, LP's INBX position evolved
PFM Health Sciences, LP first disclosed a stake in INBX in Q3 2023 at 288,617 shares (US$5.3M). The position peaked in Q3 2026 at 320,331 shares, worth US$32.1M. Across 13 filings, PFM Health Sciences, LP increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 320,331 shares valued at US$32.1M — an increase of 11,946 shares quarter over quarter.. Notable position changes include a 91% trim in Q1 2024, a 183% increase in Q2 2024 (shares rose 11% over the following quarter), a 224% increase in Q1 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 288.62K | $5.30M | New |
| Q4 2023 | 537.96K | $20.44M | Add |
| Q1 2024 | 47.92K | $1.68M | Reduce |
| Q2 2024 | 135.55K | $1.92M | Add |
| Q3 2024 | 135.55K | $2.12M | Hold |
| Q4 2024 | 135.55K | $2.09M | Hold |
| Q1 2025 | 439.28K | $6.15M | Add |
| Q2 2025 | 244.26K | $3.49M | Reduce |
| Q3 2025 | 239.64K | $8.07M | Reduce |
| Q4 2025 | 265.52K | $20.98M | Add |
| Q1 2026 | 305.43K | $20.53M | Add |
| Q2 2026 | 308.38K | $29.22M | Add |
| Q3 2026 | 320.33K | $32.06M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 40 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$123.0M), Sanofi (US$115.9M), Schonfeld Strategic Advisors LLC (US$66.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.30M sh · $122.96M · Q2 2026
- Sanofi 1.16M sh · $115.89M · Q3 2026
- Schonfeld Strategic Advisors LLC 697.59K sh · $66.10M · Q2 2026
- Sofinnova Investments, Inc. 391.62K sh · $39.19M · Q3 2026
- Parkman Healthcare Partners LLC 360.26K sh · $36.05M · Q3 2026
- First Turn Management, LLC 171.51K sh · $17.16M · Q3 2026
- Trails Edge Capital Partners, LP 170.00K sh · $17.01M · Q3 2026
More on PFM Health Sciences, LP
FAQ
How long has PFM Health Sciences, LP held INBX?
PFM Health Sciences, LP has disclosed INBX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is PFM Health Sciences, LP's current position in INBX?
As of Q3 2026, PFM Health Sciences, LP holds 320.33K shares of INBX (INHIBRX BIOSCIENCES INC), valued at $32.06M, representing 3.28% of its reported portfolio and ranking #6.
Has PFM Health Sciences, LP been buying or selling INBX?
In the latest 13F filing (Q3 2026), PFM Health Sciences, LP increased its position in INBX. The position peaked in Q3 2026 at 320.33K shares.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Schonfeld Strategic Advisors LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.